One explanation is that both NMDAR inhibition and stimulation converge on the activation of BDNF/mTOR signaling, indicating both receptor antagonists and agonists may be enlisted in treating depression (Chan et al., 2016). The gene discussed is MTOR; the disease is depressive disorder.